These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

817 related items for PubMed ID: 29912399

  • 1. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
    Stone GG, Newell P, Gasink LB, Broadhurst H, Wardman A, Yates K, Chen Z, Song J, Chow JW.
    J Antimicrob Chemother; 2018 Sep 01; 73(9):2519-2523. PubMed ID: 29912399
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programme.
    Torres A, Wible M, Tawadrous M, Irani P, Stone GG, Quintana A, Debabov D, Burroughs M, Bradford PA, Kollef M.
    J Antimicrob Chemother; 2023 Nov 06; 78(11):2672-2682. PubMed ID: 37700689
    [Abstract] [Full Text] [Related]

  • 3. Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme.
    Cheng K, Newell P, Chow JW, Broadhurst H, Wilson D, Yates K, Wardman A.
    Drug Saf; 2020 Aug 06; 43(8):751-766. PubMed ID: 32602065
    [Abstract] [Full Text] [Related]

  • 4. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.
    Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB.
    Lancet Infect Dis; 2016 Jun 06; 16(6):661-673. PubMed ID: 27107460
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.
    Stone GG, Bradford PA, Yates K, Newell P.
    J Antimicrob Chemother; 2017 May 01; 72(5):1396-1399. PubMed ID: 28088768
    [Abstract] [Full Text] [Related]

  • 7. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ, Rybak JM, Rybak MJ.
    Pharmacotherapy; 2015 Aug 01; 35(8):755-70. PubMed ID: 26289307
    [Abstract] [Full Text] [Related]

  • 8. In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin American Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015.
    Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF.
    Antimicrob Agents Chemother; 2019 Apr 01; 63(4):. PubMed ID: 30670424
    [Abstract] [Full Text] [Related]

  • 9. In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections.
    Stone GG, Newell P, Bradford PA.
    Antimicrob Agents Chemother; 2018 Jul 01; 62(7):. PubMed ID: 29686147
    [Abstract] [Full Text] [Related]

  • 10. In Vitro Activity of Ceftazidime-Avibactam against Isolates from Respiratory and Blood Specimens from Patients with Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia, in a Phase 3 Clinical Trial.
    Stone GG, Bradford PA, Tawadrous M, Taylor D, Cadatal MJ, Chen Z, Chow JW.
    Antimicrob Agents Chemother; 2020 Apr 21; 64(5):. PubMed ID: 32071051
    [Abstract] [Full Text] [Related]

  • 11. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS, Castanheira M, Flamm RK.
    Antimicrob Agents Chemother; 2017 Apr 21; 61(4):. PubMed ID: 28069649
    [Abstract] [Full Text] [Related]

  • 12. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.
    Drugs; 2019 Feb 21; 79(3):271-289. PubMed ID: 30712199
    [Abstract] [Full Text] [Related]

  • 13. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates.
    MacVane SH, Crandon JL, Nichols WW, Nicolau DP.
    Antimicrob Agents Chemother; 2014 Nov 21; 58(11):6913-9. PubMed ID: 25223999
    [Abstract] [Full Text] [Related]

  • 14. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the In Vitro Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa.
    Yin D, Wu S, Yang Y, Shi Q, Dong D, Zhu D, Hu F, China Antimicrobial Surveillance Network (CHINET) Study Group.
    Antimicrob Agents Chemother; 2019 Apr 21; 63(4):. PubMed ID: 30617091
    [Abstract] [Full Text] [Related]

  • 15. Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program.
    Mazuski JE, Wagenlehner F, Torres A, Carmeli Y, Chow JW, Wajsbrot D, Stone GG, Irani P, Bharucha D, Cheng K, Tawadrous M.
    Infect Dis Ther; 2021 Dec 21; 10(4):2399-2414. PubMed ID: 34374952
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017.
    Stone GG, Seifert H, Nord CE.
    Int J Antimicrob Agents; 2020 Sep 21; 56(3):106045. PubMed ID: 32522673
    [Abstract] [Full Text] [Related]

  • 17. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
    Shirley M.
    Drugs; 2018 Apr 21; 78(6):675-692. PubMed ID: 29671219
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.
    Sader HS, Castanheira M, Shortridge D, Mendes RE, Flamm RK.
    Antimicrob Agents Chemother; 2017 Nov 21; 61(11):. PubMed ID: 28827415
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.